<DOC>
	<DOCNO>NCT00743769</DOCNO>
	<brief_summary>The purpose study determine whether intravenous administration single- multiple-ascending dos Thymosin Beta 4 safe tolerable healthy volunteer .</brief_summary>
	<brief_title>A Phase 1 Safety Study Intravenous Administration Thymosin Beta Healthy Volunteers</brief_title>
	<detailed_description>The cardio-protective effect Tβ4 treatment show permanently ligate mouse model.The author demonstrate systemic Tβ4 treatment ( intraperitoneal , intracardiac , i.p . plus intracardiac ) every third day enhance early myocyte survival significantly improve cardiac function . Several week heart attack , evident mouse treat Tβ4 less muscle damage strong heart compare mice treat placebo . Specifically , Tβ4 treatment significantly improve fractional shorten 60 % ejection fraction 100 % myocardial salvage 53 % compare control .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<criteria>In good health underlie medical condition , accord Investigator , would place subject risk Having give write informed consent Evidence malignancy Use tobacco product within 7 year study entry Pregnant lactate woman History drug abuse Clinically significant abnormal screen ECG Abnormal vital sign Use systemic steroidal therapy ) , immunotherapy , cytotoxic , chemotherapy investigational drug device within 30 day study entry . Topical steroid allow Women , 40 year age , mammography within one year study entry Men woman , 50 year age , sigmoidoscopy within 5 year colonoscopy within 10 year study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Myocardial Infarction</keyword>
	<keyword>Myocardial Ischemia</keyword>
	<keyword>Myocardial Diseases</keyword>
	<keyword>Infarction</keyword>
</DOC>